A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

Trial Profile

A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Depatuxizumab mafodotin (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms Intellance1
  • Sponsors AbbVie
  • Most Recent Events

    • 12 Jan 2017 Planned End Date changed from 1 Mar 2020 to 1 Apr 2020.
    • 08 Oct 2015 Status changed from planning to recruiting, as reported by ClinicalTrials.gov.
    • 14 Nov 2014 Based on the results of a phase I study, AbbVie will advance ABT 414 into this randomised phase II trial in patients with glioblastoma multiforme, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top